New immune therapy trial for tough thyroid cancers
NCT ID NCT03753919
Summary
This study tested whether a combination of two immunotherapy drugs (durvalumab and tremelimumab) could help control advanced thyroid cancers that had stopped responding to standard treatments. It enrolled 79 adults with different types of aggressive thyroid cancer that had spread. The main goal was to see if the treatment could stop the cancer from growing for at least 6 months and to monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC THYROID PAPILLARY CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clínica Universidad de Navarra
Pamplona, Spain
-
Complejo Hospitalario Universitario de Vigo (CHUVI)
Vigo, 36036, Spain
-
Hospital Clínic Barcelona
Barcelona, Spain
-
Hospital Clínico San Carlos
Madrid, Spain
-
Hospital General Universitario Morales Meseguer
Murcia, Spain
-
Hospital Provincial de Castellón
Castellon, Valencia, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, Spain
-
Hospital Universitario 12 de Octubre
Madrid, Spain
-
Hospital Universitario HM Sanchinarro
Madrid, Spain
-
Hospital Universitario La Paz
Madrid, Spain
-
Hospital Universitario Ramón y Cajal
Madrid, Spain
-
Hospital Universitario Virgen de la Victoria
Málaga, Spain
-
Instituto Catalán de Oncología de Hospitalet
L'Hospitalet de Llobregat, Barcelona, 08908, Spain
-
Instituto Valenciano de Oncología
Valencia, 46009, Spain
-
MD Anderson Cancer Center
Madrid, 28033, Spain
Conditions
Explore the condition pages connected to this study.